Responses
Regular and young investigator award abstracts
Clinical trials in progress
324 BDB001, a Toll-Like receptor 7 and 8 (TLR7/8) agonist, can be safely administered intravenously and shows clinical responses in advanced solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.